Correlation between reduction in systemic CL and renal or non-renal CL for DDIs involving intravenous administration of P-gp substrate drugs. Each symbol represents one clinical DDI case (Table 1). Numbers in the symbol represent inhibitors in the DDI study (1: amiodarone, 2: cyclosporine, 3: quinidine, 4: quinine, 5: ritonavir, 6: spironolactone, 7: valspodar (PSC833), 8: verapamil). CL, clearance; DDI, drug-drug interaction.